Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.

Trial Details

NCT ID
NCT04470024
Phase
PHASE1
Sponsor
Providence Health & Services
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • INCAGN01876
  • INCMGA00012
  • DPV-001
Locations (sample)
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 (Appendix C)
  • Age 18 years or above.
  • Laboratory values:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →